Artemin, a member of the glial cell line-derived neurotrophic factor family of ligands, is her2-regulated and mediates acquired trastuzumab resistance by promoting cancer stem cell-like behavior in mammary carcinoma cells

Journal of Biological Chemistry

Volumn 289, Issue 23, 2014, Pages 16057-16071

  Ding, Keshuo ^a   Banerjee, Arindam ^b   Tan, Sheng ^a   Zhao, Junsong ^a   Zhuang, Qian ^a   Li, Rui ^a   Qian, Pengxu ^a   Liu, Suling ^a   Wu, Zheng Sheng ^a,c,d   Lobie, Peter E ^b,e   Zhu, Tao ^a  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; DISEASES; ENZYME INHIBITION; LIGANDS; POPULATION STATISTICS; STEM CELLS;

ACQUIRED RESISTANCE; ARTEMIN; CANCER STEM CELLS; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; IN-VITRO; MAMMARY CARCINOMA; MAMMARY CARCINOMA CELL; TRASTUZUMAB;

MONOCLONAL ANTIBODIES;

ARTEMIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NEU DIFFERENTIATION FACTOR; SMALL INTERFERING RNA; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER STEM CELL; CARCINOMA CELL; CELL POPULATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESISTANCE; DRUG SENSITIVITY; FEMALE; GLIAL CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM;

BREAST CANCER; CANCER STEM CELLS; CHEMORESISTANCE; ONCOGENE; TUMOR METASTASES;

ANTIBODIES, MONOCLONAL, HUMANIZED; BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA PRIMERS; DRUG RESISTANCE, NEOPLASM; FEMALE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; NEOPLASTIC STEM CELLS; NERVE TISSUE PROTEINS; POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2;

EID: 84902182083     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.529552     Document Type: Article

References (52)

1. Stern, D. F. (2000) Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases. Breast Cancer Res. 2, 176-183
2. Wong, A. L., and Lee, S. C. (2012) Mechanisms of resistance to trastuzumab and novel therapeutic strategies in HER2-positive breast cancer. Int. J. Breast Cancer 2012, 415170
3. Korkaya, H., Kim, G. I., Davis, A., Malik, F., Henry, N. L., Ithimakin, S., Quraishi, A. A., Tawakkol, N., D'Angelo, R., Paulson, A. K., Chung, S., Luther, T., Paholak, H. J., Liu, S., Hassan, K. A., Zen, Q., Clouthier, S. G., and Wicha, M. S. (2012) Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2β breast cancer by expanding the cancer stem cell population. Mol. Cell 47, 570-584
4. Gradishar, W. J. (2013) Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab. Ann. Oncol. 24, 2492-2500
5. Huang, Y., Fu, P., and Fan, W. (2013) Novel targeted therapies to overcome trastuzumab resistance in HER2-overexpressing metastatic breast cancer. Curr. Drug Targets 14, 889-898
6. Nahta, R., Yuan, L. X., Zhang, B., Kobayashi, R., and Esteva, F. J. (2005) Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 65, 11118-11128
7. Shattuck, D. L., Miller, J. K., Carraway, K. L., 3rd, and Sweeney, C. (2008) Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res. 68, 1471-1477
8. Airaksinen, M. S., and Saarma, M. (2002) The GDNF family: signalling, biological functions and therapeutic value. Nat. Rev. Neurosci. 3, 383-394
9. Bespalov, M. M., Sidorova, Y. A., Tumova, S., Ahonen-Bishopp, A., Magalhães, A. C., Kulesskiy, E., Paveliev, M., Rivera, C., Rauvala, H., and Saarma, M. (2011) Heparan sulfate proteoglycan syndecan-3 is a novel receptor for GDNF, neurturin, and artemin. J. Cell Biol. 192, 153-169
10. Wu, Z. S., Pandey, V., Wu, W. Y., Ye, S., Zhu, T., and Lobie, P. E. (2013) Prognostic significance of the expression of GFRβ1, GFRβ3, and syndecan-3, proteins binding Artemin, in mammary carcinoma. BMC Cancer 13, 34
11. Banerjee, A., Wu, Z. S., Qian, P., Kang, J., Pandey, V., Liu, D. X., Zhu, T., and Lobie, P. E. (2011) Artemin synergizes with TWIST1 to promote metastasis and poor survival outcome in patients with ER-negative mammary carcinoma. Breast Cancer Res. 13, R112
12. Banerjee, A., Wu, Z. S., Qian, P. X., Kang, J., Liu, D. X., Zhu, T., and Lobie, P. E. (2012) Artemin promotes de novo angiogenesis in ER-negative mammary carcinoma through activation of TWIST1-VEGF-A signalling. PLoS One 7, e50098
13. Kang, J., Perry, J. K., Pandey, V., Fielder, G. C., Mei, B., Qian, P. X., Wu, Z. S., Zhu, T., Liu, D. X., and Lobie, P. E. (2009) Artemin is oncogenic for human mammary carcinoma cells. Oncogene 28, 2034-2045
14. Pandey, V., Jung, Y., Kang, J., Steiner, M., Qian, P. X., Banerjee, A., Mitchell, M. D., Wu, Z. S., Zhu, T., Liu, D. X., and Lobie, P. E. (2010) Artemin reduces sensitivity to doxorubicin and paclitaxel in endometrial carcinoma cells through specific regulation of CD24. Transl. Oncol. 3, 218-229
15. Banerjee, A., Qian, P., Wu, Z. S., Ren, X., Steiner, M., Bougen, N. M., Liu, S., Liu, D. X., Zhu, T., and Lobie, P. E. (2012) Artemin stimulates radioand chemo-resistance by promoting TWIST1-BCL-2-dependent cancer stem cell-like behavior in mammary carcinoma cells. J. Biol. Chem. 287, 42502-42515
16. Kang, J., Qian, P. X., Pandey, V., Perry, J. K., Miller, L. D., Liu, E. T., Zhu, T., Liu, D. X., and Lobie, P. E. (2010) Artemin is estrogen-regulated and mediates antiestrogen resistance in mammary carcinoma. Oncogene 29, 3228-3240
17. Dean, M., Fojo, T., and Bates, S. (2005) Tumour stem cells and drug resistance. Nat. Rev. Cancer 5, 275-284
18. Korkaya, H., Paulson, A., Iovino, F., and Wicha, M. S. (2008) HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 27, 6120-6130
19. Crawford, A., and Nahta, R. (2011) Targeting Bcl-2 in herceptin-resistant breast cancer cell lines. Curr. Pharmacogenomics Person. Med. 9, 184-190
20. Nahta, R. (2012) New developments in the treatment of HER2-positive breast cancer. Breast Cancer 4, 53-64
21. Lang, J. Y., Hsu, J. L., Meric-Bernstam, F., Chang, C. J., Wang, Q., Bao, Y., Yamaguchi, H., Xie, X., Woodward, W. A., Yu, D., Hortobagyi, G. N., and Hung, M. C. (2011) BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment. Cancer Cell 20, 341-356
22. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182
23. Liu, D. X., and Lobie, P. E. (2007) Transcriptional activation of p53 by Pitx1. Cell Death Differ. 14, 1893-1907
24. Pandey, V., Perry, J. K., Mohankumar, K. M., Kong, X. J., Liu, S. M., Wu, Z. S., Mitchell, M. D., Zhu, T., and Lobie, P. E. (2008) Autocrine human growth hormone stimulates oncogenicity of endometrial carcinoma cells. Endocrinology 149, 3909-3919
25. Klapper, L. N., Glathe, S., Vaisman, N., Hynes, N. E., Andrews, G. C., Sela, M., and Yarden, Y. (1999) The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stromaderived growth factors. Proc. Natl. Acad. Sci. U. S. A. 96, 4995-5000
26. Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S., Ratzkin, B. J., and Yarden, Y. (1996) A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol. Cell. Biol. 16, 5276-5287
27. Park, B. H., and Davidson, N. E. (2007) PI3 kinase activation and response to trastuzumab therapy: what's neu with herceptin resistance? Cancer Cell 12, 297-299
28. Tseng, P. H., Wang, Y. C., Weng, S. C., Weng, J. R., Chen, C. S., Brueggemeier, R. W., Shapiro, C. L., Chen, C. Y., Dunn, S. E., Pollak, M., and Chen, C. S. (2006) Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositidedependent kinase-1 inhibitor. Mol. Pharmacol. 70, 1534-1541
29. Chakrabarty, A., Bhola, N. E., Sutton, C., Ghosh, R., Kuba, M. G., Dave, B., Chang, J. C., and Arteaga, C. L. (2013) Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. Cancer Res. 73, 1190-1200
30. Bedard, P. L., Cardoso, F., and Piccart-Gebhart, M. J. (2009) Stemming resistance to HER-2 targeted therapy. J. Mammary Gland Biol. Neoplasia 14, 55-66
31. Ginestier, C., Hur, M. H., Charafe-Jauffret, E., Monville, F., Dutcher, J., Brown, M., Jacquemier, J., Viens, P., Kleer, C. G., Liu, S., Schott, A., Hayes, D., Birnbaum, D., Wicha, M. S., and Dontu, G. (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1, 555-567
32. Liu, S., Dontu, G., and Wicha, M. S. (2005) Mammary stem cells, selfrenewal pathways, and carcinogenesis. Breast Cancer Res. 7, 86-95
33. Reya, T., Morrison, S. J., Clarke, M. F., and Weissman, I. L. (2001) Stem cells, cancer, and cancer stem cells. Nature 414, 105-111
34. Duru, N., Fan, M., Candas, D., Menaa, C., Liu, H. C., Nantajit, D., Wen, Y., Xiao, K., Eldridge, A., Chromy, B. A., Li, S., Spitz, D. R., Lam, K. S., Wicha, M. S., and Li, J. J. (2012) HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells. Clin. Cancer Res. 18, 6634-6647
35. Minami, T., Kijima, T., Otani, Y., Kohmo, S., Takahashi, R., Nagatomo, I., Hirata, H., Suzuki, M., Inoue, K., Takeda, Y., Kida, H., Tachibana, I., and Kumanogoh, A. (2012) HER2 as therapeutic target for overcoming ATPbinding cassette transporter-mediated chemoresistance in small cell lung cancer. Mol. Cancer Ther. 11, 830-841
36. Ithimakin, S., Day, K. C., Malik, F., Zen, Q., Dawsey, S. J., Bersano-Begey, T. F., Quraishi, A. A., Ignatoski, K. W., Daignault, S., Davis, A., Hall, C. L., Palanisamy, N., Heath, A. N., Tawakkol, N., Luther, T. K., Clouthier, S. G., Chadwick, W. A., Day, M. L., Kleer, C. G., Thomas, D. G., Hayes, D. F., Korkaya, H., and Wicha, M. S. (2013) HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res. 73, 1635-1646
37. Oliveras-Ferraros, C., Corominas-Faja, B., Cufí, S., Vazquez-Martin, A., Martin-Castillo, B., Iglesias, J. M., López-Bonet, E., Martin, Á. G., and Menendez, J. A. (2012) Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin). Cell Cycle 11, 4020-4032
38. Wu, Y., Ginther, C., Kim, J., Mosher, N., Chung, S., Slamon, D., and Vadgama, J. V. (2012) Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells. Mol. Cancer Res. 10, 1597-1606
39. Milella, M., Trisciuoglio, D., Bruno, T., Ciuffreda, L., Mottolese, M., Cianciulli, A., Cognetti, F., Zangemeister-Wittke, U., Del Bufalo, D., and Zupi, G. (2004) Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene-amplified breast cancer cells. Clin. Cancer Res. 10, 7747-7756
40. Dawson, S. J., Makretsov, N., Blows, F. M., Driver, K. E., Provenzano, E., Le Quesne, J., Baglietto, L., Severi, G., Giles, G. G., McLean, C. A., Callagy, G., Green, A. R., Ellis, I., Gelmon, K., Turashvili, G., Leung, S., Aparicio, S., Huntsman, D., Caldas, C., and Pharoah, P. (2010) BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br. J. Cancer 103, 668-675
41. Tawfik, K., Kimler, B. F., Davis, M. K., Fan, F., and Tawfik, O. (2012) Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triplenegative" tumors. Hum. Pathol. 43, 23-30
42. Yang, Q., Moran, M. S., and Haffty, B. G. (2009) Bcl-2 expression predicts local relapse for early-stage breast cancer receiving conserving surgery and radiotherapy. Breast Cancer Res. Treat. 115, 343-348
43. Youle, R. J., and Strasser, A. (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9, 47-59
44. Lu, Y., Zi, X., and Pollak, M. (2004) Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int. J. Cancer 108, 334-341
45. Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D., and Pollak, M. (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J. Natl. Cancer Inst. 93, 1852-1857
46. Sariola, H., and Saarma, M. (2003) Novel functions and signalling pathways for GDNF. J. Cell Sci. 116, 3855-3862
47. Bilak, M. M., and Kuncl, R. W. (2001) Delayed application of IGF-I and GDNF can rescue already injured postnatal motor neurons. Neuroreport 12, 2531-2535
48. D'Costa, A. P., Prevette, D. M., Houenou, L. J., Wang, S., Zackenfels, K., Rohrer, H., Zapf, J., Caroni, P., and Oppenheim, R. W. (1998) Mechanisms of insulin-like growth factor regulation of programmed cell death of developing avian motoneurons. J. Neurobiol. 36, 379-394
49. Nahta, R., and O'Regan, R. M. (2012) Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers. Breast Cancer Res. Treat. 135, 39-48
50. Benz, C. C., Scott, G. K., Sarup, J. C., Johnson, R. M., Tripathy, D., Coronado, E., Shepard, H. M., and Osborne, C. K. (1992) Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res. Treat. 24, 85-95
51. Kurokawa, H., Lenferink, A. E., Simpson, J. F., Pisacane, P. I., Sliwkowski, M. X., Forbes, J. T., and Arteaga, C. L. (2000) Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res. 60, 5887-5894
52. Pietras, R. J., Arboleda, J., Reese, D. M., Wongvipat, N., Pegram, M. D., Ramos, L., Gorman, C. M., Parker, M. G., Sliwkowski, M. X., and Slamon, D. J. (1995) HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10, 2435-2446